This article is more than 5 years old. Information may no longer be current.

OculusGen biodegradable collagen matrix approved in Europe, Canada

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

TAIPEI, Taiwan — The European Union has granted marketing approval to OculusGen Biomedical Inc. for its OculusGen biodegradable collagen matrix for use in trabeculectomy, the company announced.

OculusGen also received the Canadian Medical Devices Conformity Assessment System certificate and plans to submit a Canadian product license soon, according to a press release from the company.

The biodegradable collagen matrix is an implantable polymer scaffold that guides fibroblasts to create planned bleb structures for glaucoma filtration and other ophthalmic surgeries, according to the release.